<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Chapter 2 Results and Discussion | Identifying immune features that determine immunogenicity and influence prognosis in chemotherapy treated diffuse large B cell lymphoma (DLBCL)</title>
<meta name="author" content="Shruti Sridhar">
<meta name="generator" content="bookdown 0.26.2 with bs4_book()">
<meta property="og:title" content="Chapter 2 Results and Discussion | Identifying immune features that determine immunogenicity and influence prognosis in chemotherapy treated diffuse large B cell lymphoma (DLBCL)">
<meta property="og:type" content="book">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="Chapter 2 Results and Discussion | Identifying immune features that determine immunogenicity and influence prognosis in chemotherapy treated diffuse large B cell lymphoma (DLBCL)">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.3.1.9000/transition.js"></script><script src="libs/bs3compat-0.3.1.9000/tabs.js"></script><script src="libs/bs3compat-0.3.1.9000/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<style type="text/css">
    /* Used with Pandoc 2.11+ new --citeproc when CSL is used */
    div.csl-bib-body { }
    div.csl-entry {
      clear: both;
        }
    .hanging div.csl-entry {
      margin-left:2em;
      text-indent:-2em;
    }
    div.csl-left-margin {
      min-width:2em;
      float:left;
    }
    div.csl-right-inline {
      margin-left:2em;
      padding-left:1em;
    }
    div.csl-indent {
      margin-left: 2em;
    }
  </style>
<meta name="description" content="2.1 Pathway Analysis By applying GSEA to the GOYA RNA Seq dataset, we obtain a broad overview of the enriched pathways in ‘immune cell type rich’ versus ‘immune cell type poor’ samples. Normalized...">
<meta property="og:description" content="2.1 Pathway Analysis By applying GSEA to the GOYA RNA Seq dataset, we obtain a broad overview of the enriched pathways in ‘immune cell type rich’ versus ‘immune cell type poor’ samples. Normalized...">
<meta name="twitter:description" content="2.1 Pathway Analysis By applying GSEA to the GOYA RNA Seq dataset, we obtain a broad overview of the enriched pathways in ‘immune cell type rich’ versus ‘immune cell type poor’ samples. Normalized...">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Identifying immune features that determine immunogenicity and influence prognosis in chemotherapy treated diffuse large B cell lymphoma (DLBCL)</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">Preliminary Content</a></li>
<li><a class="" href="introduction.html">Introduction</a></li>
<li><a class="" href="rmd-basics.html"><span class="header-section-number">1</span> Methodology</a></li>
<li><a class="active" href="results-and-discussion.html"><span class="header-section-number">2</span> Results and Discussion</a></li>
<li><a class="" href="conclusion.html">Conclusion</a></li>
<li class="book-part">Appendix</li>
<li><a class="" href="appendix.html"><span class="header-section-number">A</span> Appendix</a></li>
<li><a class="" href="references.html">References</a></li>
</ul>

        <div class="book-extra">
          
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="results-and-discussion" class="section level1" number="2">
<h1>
<span class="header-section-number">2</span> Results and Discussion<a class="anchor" aria-label="anchor" href="#results-and-discussion"><i class="fas fa-link"></i></a>
</h1>
<div id="pathway-analysis-1" class="section level2" number="2.1">
<h2>
<span class="header-section-number">2.1</span> Pathway Analysis<a class="anchor" aria-label="anchor" href="#pathway-analysis-1"><i class="fas fa-link"></i></a>
</h2>
<p>By applying GSEA to the GOYA RNA Seq dataset, we obtain a broad overview of the enriched pathways in ‘immune cell type rich’ versus ‘immune cell type poor’ samples. Normalized enrichment scores (NES) were plotted for each pathway with the size of the data point representing the number of genes enriched for that pathway. A higher NES indicates a more significant enrichment of the pathway. The data points were colour coded with respect to the p-value with the lighter shade implying higher p value and lower statistically significance.</p>
<p>DLBCL arises from the germinal center and shows two distinct subtypes: germinal-center B-cell-like (GCB) DLBCL and activated B-cell-like (ABC) DLBCL. Germinal-center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) are derived from normal germinal-center centroblasts whereas Activated B-cell-like (ABC) diffuse large B-cell lymphomas (DLBCLs) are derived from plasmablasts27.</p>
<p>Certain transformations of the GCB result in malignancy such as deregulation of BCL2, PI3K/mTOR pathway, p53 mutations and MDM2 gain/amplification28. Deregulation of anti apoptotic BCL2 leads to overexpression of BCL2, making the cell resist cell death.</p>
<p>ABC DLBCL however, shows constitutive activation of the oncogenic nuclear factor kappa B (NF-kB) signaling pathway as well as de-regulation BCL2 protein28. NF-κB activity is required for normal B cell development and survival. Lymphoid malignancies typically circumvent cell death by activation of the NFkB pathway. In particular for B cells, NFkB activation is seen downstream of several receptors including BCR, CD40, the B-cell–activating factor (BAFF) receptor, and Toll-like receptors (TLRs)29</p>
<p>BCL6, a transcription repressor is also known to play a causative role in lymphomagenesis. STAT3 is a negative transcriptional regulator of BCL6. Sustained STAT3 activity (for proliferation and survival) is seen in ABC DLBCL cells, suggesting that chemoresistance and consequently poorer outcomes, exhibited by ABC DLBCL could be determined by simultaneous activation of both NFkB and STAT328,30</p>
<p>Further, lymphocytes and lymphoid malignancies depend on cytokine stimulation for growth and survival. B cell microenvironment interaction is influenced by cytokines such as interleukin (IL) 4, IL6, IL10 and IL2131</p>
<p>The GSEA comparisons (Supplementary Material Fig 1a-h) are for DLBCL with high immune cell infiltration vs low immune cell infiltration. Merdan et al 32 evaluated the CIBERSORT deconvolution scores for different immune subtypes and stratified the scores according to clinical risk groups. They established an association between the relative proportions of the immune cell types within subgroups of DLBCL patients by various clinical traits including cell of origin. It was seen that M0 macrophages, memory resting CD4 + T-cells and CD8+ T cells show greater infiltration particularly in GCB DLBCL samples. This could suggest that the pathways (such as complement, inflammatory response for M0, response to DNA damage for CD4+ memory resting and interferon gamma and alpha for CD8+ T cells) that show greater enrichment than STAT3 and NFkB (which are the pathways active in ABC DLBCL) could represent pathways active in GCB DLBCL that drive the infiltration of these cell types.</p>
</div>
<div id="sting-cgas-pathway" class="section level2" number="2.2">
<h2>
<span class="header-section-number">2.2</span> STING cGAS Pathway<a class="anchor" aria-label="anchor" href="#sting-cgas-pathway"><i class="fas fa-link"></i></a>
</h2>
<div class="figure" style="text-align: center">
<span style="display:block;" id="fig:STING"></span>
<img src="figure/sting.jpg" alt="STING Pathway" width="342"><p class="caption">
Figure 2.1: STING Pathway
</p>
</div>
<p>Abnormal localization of DNA in the cytosol elicits an immune response through the cGAS-STING pathway. cGAS binds to DNA in the cytosol and converts ATP and GTP into 2′3′-cGAMP. cGAMP then binds to STING on the ER to trigger STING trafficking to vesicles. cGAMP-bound STING activates the downstream kinases TBK1 and IKK to activate the transcription factors IRF3 and NF-κB, respectively. These transcription factors induce expression of type I IFNs and cytokines, which propagate the immune response in an autocrine and paracrine manner33</p>
</div>
<div id="sting-correlation-analysis-1" class="section level2" number="2.3">
<h2>
<span class="header-section-number">2.3</span> STING Correlation Analysis<a class="anchor" aria-label="anchor" href="#sting-correlation-analysis-1"><i class="fas fa-link"></i></a>
</h2>
<p>Through an investigation evaluating the prognostic significance of a set of immunological features reflective of innate and adaptive immunity in DLBCL, the Jeyasekharan lab identified the inflammatory mediator STING as being correlated with a favourable prognosis.</p>
<p>The correlation between STING expression and immune cell infiltration was examined for three RNA Seq datasets. The CIBERSORT Scores for each immune cell was divided into CIBERSORT high quartile (Q4), Interquartile range (IQR) and CIBERSORT low quartile (Q1). The TPM counts for STING expression was plotted as a continuous variable for each quartile and one way ANOVA and subsequent p value was used to determine statistical significance.</p>
<p>Overall, a positive trend was noticed across immune cells with the CIBERSORT high quartile (Q4) showing higher TPM when compared to the CIBERSORT low quartile (Q1) suggesting a positive correlation between STING expression and immune cell infiltration.</p>
<p>Fig 3a captures the trend of the median of STING expression for CIBESORT high quartile being greater than the median of STING expression for the CIBERSORT low quartile across all the datasets with the lighter color indicating higher STING expression. Fig 3b captures the magnitude of difference of STING expression between CIBERSORT high quartile and CIBERSORT low quartile where a lighter color represents a higher magnitude of difference.</p>
<p>Both heatmaps confirm the initial trend and hint at the role of STING expression correlating with greater immune cell infiltration.</p>
</div>
<div id="sting-gsea-analysis" class="section level2" number="2.4">
<h2>
<span class="header-section-number">2.4</span> STING GSEA Analysis<a class="anchor" aria-label="anchor" href="#sting-gsea-analysis"><i class="fas fa-link"></i></a>
</h2>
<div class="figure">
<span style="display:block;" id="fig:sample-map"></span>
<iframe src="https://handsondataviz.github.io/leaflet-map-simple/" width="672" height="375px" data-external="1">
</iframe>
<p class="caption">
Figure 2.2: (ref:sample-map)
</p>
</div>


</div>
</div>
  <div class="chapter-nav">
<div class="prev"><a href="rmd-basics.html"><span class="header-section-number">1</span> Methodology</a></div>
<div class="next"><a href="conclusion.html">Conclusion</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#results-and-discussion"><span class="header-section-number">2</span> Results and Discussion</a></li>
<li><a class="nav-link" href="#pathway-analysis-1"><span class="header-section-number">2.1</span> Pathway Analysis</a></li>
<li><a class="nav-link" href="#sting-cgas-pathway"><span class="header-section-number">2.2</span> STING cGAS Pathway</a></li>
<li><a class="nav-link" href="#sting-correlation-analysis-1"><span class="header-section-number">2.3</span> STING Correlation Analysis</a></li>
<li><a class="nav-link" href="#sting-gsea-analysis"><span class="header-section-number">2.4</span> STING GSEA Analysis</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
          
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3">
    <p>"<strong>Identifying immune features that determine immunogenicity and influence prognosis in chemotherapy treated diffuse large B cell lymphoma (DLBCL)</strong>" was written by Shruti Sridhar. It was last built on May 2022.</p>
  </div>

  <div class="col-12 col-md-6 mt-3">
    <p>This book was built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package.</p>
  </div>

</div></div>
</footer>
</body>
</html>
